The impact of slower walking speed on activities of daily living in patients with multiple sclerosis

International Journal of Clinical Practice

Volumn 66, Issue 11, 2012, Pages 1088-1094

  Yildiz, M ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND HEALTH; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PATIENT MOBILITY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; WALKING AID; WALKING SPEED;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; QUALITY OF LIFE; QUESTIONNAIRES; WALKING;

EID: 84867529833     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12003     Document Type: Article

References (49)

1. Confavreux C, Vukusic S, Moreau T, Adeleine P,. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430-8.
2. Larocca NG,. Impact of walking impairment in multiple sclerosis: perspectives of patients and care partners. Patient 2011; 4: 189-201.
3. Scalfari A, Neuhaus A, Degenhardt A, et al., The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010; 133: 1914-29.
4. Sutliff MH,. Contribution of impaired mobility to patient burden in multiple sclerosis. Curr Med Res Opin 2010; 26: 109-19.
5. van Asch P,. Impact of mobility impairment in multiple sclerosis 2-patient perspectives. Eur Neurol Rev 2011; 6: 115-20.
6. Society NMS. National Multiple Sclerosis Society. [accessed 14 October 2011]; Available from: http://www.nationalmssociety.org/about-multiple- sclerosis/what-we-know-about-ms/who-gets-ms/index.aspx
7. Cross AH, Waubant E, Antibodies to Potassium Channels in Multiple Sclerosis. N Engl J Med 2012; 367: 172-4.
8. Gottberg K, Einarsson U, Ytterberg C, et al., Health-related quality of life in a population-based sample of people with multiple sclerosis in Stockholm County. Mult Scler 2006; 12: 605-12. (Pubitemid 46940635)
9. Hemmett L, Holmes J, Barnes M, Russell N,. What drives quality of life in multiple sclerosis?. QJM 2004; 97: 671-6. (Pubitemid 39359325)
10. Zwibel HL,. Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. Adv Ther 2009; 26: 1043-57.
11. Salter AR, Cutter GR, Tyry T, et al., Impact of loss of mobility on instrumental activities of daily living and socioeconomic status in patients with MS. Curr Med Res Opin 2010; 26: 493-500.
12. Heesen C, Bohm J, Reich C, et al., Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable. Mult Scler 2008; 14: 988-91.
13. Finlayson M,. Concerns about the future among older adults with multiple sclerosis. Am J Occup Ther 2004; 57: 54-63. (Pubitemid 40310558)
14. Confavreux C, Vukusic S,. Age at disability milestones in multiple sclerosis. Brain 2006; 129: 595-605. (Pubitemid 43278222)
15. Compston A, Coles A,. Multiple sclerosis. Lancet 2008; 372: 1502-17.
16. Jones CA, Pohar SL, Warren S, et al., The burden of multiple sclerosis: a community health survey. Health Qual Life Outcomes 2008; 6: 1.
17. Kurtzke JF,. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52. (Pubitemid 14237132)
18. Fischer JS, Rudick RA, Cutter GR, Reingold SC,. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999; 5: 244-50. (Pubitemid 29405620)
19. Cohen JA, Fischer JS, Bolibrush DM, et al., Intrarater and interrater reliability of the MS functional composite outcome measure. Neurology 2000; 54: 802-6. (Pubitemid 30111332)
20. Daumer M, Neuhaus A, Ullrich D, Albrecht H,. The MSFC as outcome and surrogate marker of the EDSS in multiple sclerosis clinical trials: results of a prospective longitudinal cohort study. Presented at the 5th Joint triennial congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis 2011.
21. Sosnoff JJ, Weikert M, Dlugonski D, et al., Quantifying gait impairment in multiple sclerosis using GAITRite (TM) technology. Gait & Posture 2011; 34: 145-7.
22. Cavanaugh JT, Gappmaier VO, Dibble LE, Gappmaier E,. Ambulatory activity in individuals with multiple sclerosis. J Neurol Phys Ther 2011; 35: 26-33.
23. Goldman MD, Marrie RA, Cohen JA,. Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Mult Scler 2008; 14: 383-90. (Pubitemid 351676433)
24. Phan-Ba R, Pace A, Calay P, et al., Comparison of the timed 25-foot and the 100-meter walk as performance measures in multiple sclerosis. Neurorehabil Neural Repair 2011; 25: 672-9.
25. Rajagopalan K, Jones EC, Pike J, Anderson P,. Work losses associated with walking/mobility problems among multiple sclerosis patients in 5 EU countries. Neurology 2010; 76: A608.
26. Piercy J, Rajagopalan K, Pike J, Jones EC,. Burden of walking problems in MS: analysis of caregiver and indirect costs. Neurology 2011; 76: A606.
27. Paltamaa J, Sarasoja T, Leskinen E, et al., Measures of physical functioning predict self-reported performance in self-care, mobility, and domestic life in ambulatory persons with multiple sclerosis. Arch Phys Med Rehabil 2007; 88: 1649-57. (Pubitemid 350151390)
28. Rodriguez M, Siva A, Ward J, et al., Impairment, disability, and handicap in multiple sclerosis: a population-based study in Olmsted County, Minnesota. Neurology 1994; 44: 28-33.
29. Johansson S, Ytterberg C, Claesson IM, et al., High concurrent presence of disability in multiple sclerosis. Associations with perceived health. J Neurol 2007; 254: 767-73. (Pubitemid 47012454)
30. Einarsson U, Gottberg K, Fredrikson S, et al., Activities of daily living and social activities in people with multiple sclerosis in Stockholm County. Clin Rehabil 2006; 20: 543-51. (Pubitemid 44102827)
31. Kornblith AB, La Rocca NG, Baum HM,. Employment in individuals with multiple sclerosis. Int J Rehabil Res 1986; 9: 155-65. (Pubitemid 16021310)
32. Greer JM, McCombe PA,. Role of gender in multiple sclerosis: clinical effects and potential molecular mechanisms. J Neuroimmunol 2011; 234: 7-18.
33. Vukusic S, Confavreux C,. Natural history of multiple sclerosis: risk factors and prognostic indicators. Curr Opin Neurol 2007; 20: 269-74. (Pubitemid 46743107)
34. Motl RW, Snook EM, Wynn D,. Physical activity behavior in individuals with secondary progressive multiple sclerosis. Int J MS Care 2007; 9: 139-42.
35. Tojano M, Paolicelli D, Bellacosa A,. The transition from relapsing-remitting MS to irreversible disability: clinical evaluation. Neurol Sci 2003; 24: S268-70. (Pubitemid 37493198)
36. Weinshenker BG, Bass B, Rice GP, et al., The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989; 112 (Pt 1): 133-46. (Pubitemid 19056478)
37. Creange A, Serre I, Levasseur M, et al., Walking capacities in multiple sclerosis measured by global positioning system odometer. Mult Scler 2007; 13: 220-3. (Pubitemid 46592775)
38. Schwid SR, Goodman AD, Mattson DH, et al., The measurement of ambulatory impairment in multiple sclerosis. Neurology 1997; 49: 1419-24. (Pubitemid 27495653)
39. Kieseier BC, Pozzilli C,. Assessing walking disability in multiple sclerosis. Mult Scler 2012; 18: 914-24.
40. Cadavid D, Tang YQ, O'Neill G,. Responsiveness of the Expanded Disability Status Scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis. Revista De Neurologia 2010; 51: 321-9.
41. Nortvedt MW, Riise T, Myhr KM, Nyland HI,. Quality of life in multiple sclerosis: measuring the disease effects more broadly. Neurology 1999; 53: 1098-103. (Pubitemid 29442130)
42. Schwid SR, Goodman AD, McDermott MP, et al., Quantitative functional measures in MS: what is a reliable change?. Neurology 2002; 58: 1294-6. (Pubitemid 34411881)
43. Paltamaa J, Sarasoja T, Wikstrom J, Malkia E,. Physical functioning in multiple sclerosis: a population-based study in central Finland. J Rehabil Med 2006; 38: 339-45. (Pubitemid 44644743)
44. Solari A, Ferrari G, Radice D,. A longitudinal survey of self-assessed health trends in a community cohort of people with multiple sclerosis and their significant others. J Neurol Sci 2006; 243: 13-20.
45. Kobelt G, Berg J, Lindgren P, et al., Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006; 77: 918-26. (Pubitemid 44174075)
46. Goodman AD, Brown TR, Edwards KR, et al., A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010; 68: 494-502.
47. Goodman AD, Brown TR, Krupp LB, et al., Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009; 373: 732-8.
48. Suh Y, Weikert M, Dlugonski D, et al., Physical activity, social support, and depression: possible independent and indirect associations in persons with multiple sclerosis. Psychol Health Med 2012; 17: 196-206.
49. Paparrigopoulos T, Ferentinos P, Kouzoupis A, et al., The neuropsychiatry of multiple sclerosis: focus on disorders of mood, affect and behaviour. Int Rev Psychiatry 2010; 22: 14-21.